Where Are Opioid Settlement Funds Going? A 2026 Update

Between 2021 and 2025, states received over $50 billion from opioid settlements with pharmaceutical companies. That money was supposed to expand treatment, save lives, and rebuild communities devastated by the overdose crisis. But as we move into 2026, the question everyone's asking is: where did it actually go?

If you live in Virginia, Ohio, or Pennsylvania, billions of dollars have been allocated to your state. Some of it funded meaningful change — expanded Medicaid coverage for Suboxone, more naloxone distribution, new treatment slots. But much of it disappeared into administrative costs, pilot programs that never scaled, and initiatives that sounded good in press releases but didn't reach people who needed help.

This post breaks down how settlement funds have been spent in VA, OH, and PA through early 2026, what's working, what isn't, and how you can push for evidence-based investments in your community.

How Much Money Did Each State Receive?

The national opioid settlement total reached $54 billion by the end of 2025, split among state governments, local jurisdictions, and tribes. Here's what Virginia, Ohio, and Pennsylvania were allocated:

Virginia: $530 million total

• State allocation: $318 million
• Local allocations: $212 million
• Distributed: $294 million through Q1 2026

Ohio: $1.68 billion total

• State allocation: $808 million
• Local allocations: $872 million (OneOhio Recovery Foundation)
• Distributed: $1.12 billion through Q1 2026

Pennsylvania: $1.07 billion total

• State allocation: $643 million
• Local allocations: $427 million
• Distributed: $687 million through Q1 2026

These aren't small numbers. Ohio received more settlement money per capita than almost any other state because its overdose crisis was so severe. Pennsylvania and Virginia followed similar distribution models, with roughly 60% going to state programs and 40% to counties and cities.

What Are the Funds Supposed to Be Used For?

Settlement agreements include "Exhibit E" — a list of approved uses designed to prevent misuse. The money can fund:

• Medication-assisted treatment (MAT) expansion, including Suboxone and methadone programs
• Naloxone distribution and overdose prevention
• Treatment capacity building (more providers, more beds, more telehealth access)
• Prevention programs targeting youth and at-risk populations
• Recovery support services (housing, peer support, employment programs)
• Criminal justice diversion and reentry programs
• Data infrastructure to track outcomes

Funds cannot be used for general expenses, law enforcement equipment unrelated to overdose response, or anything that doesn't directly address opioid use disorder.

Virginia: Where the Money Went

Virginia created the Opioid Abatement Authority in 2022 to manage its state-level funds. As of March 2026, here's how the $318 million state allocation has been spent:

Treatment expansion (38%): $121 million

• Medicaid reimbursement rates increased for buprenorphine prescribing, bringing 127 new providers online
• $18 million to community health centers for same-day MAT access in rural areas
• Telehealth platform grants that helped providers like Grata Health serve patients in underserved regions like southwestern Virginia

Naloxone distribution (22%): $70 million

• Free naloxone kits available at pharmacies statewide without prescription
• Training programs for first responders and community organizations
• Fentanyl test strips now legal and distributed alongside naloxone

Prevention and education (18%): $57 million

• School-based prevention programs (mixed results — more on this below)
• Public awareness campaigns about signs of opioid use disorder
• Youth sports and after-school programming as "protective factors"

Recovery housing (12%): $38 million

• Standards established for certified recovery residences
• Grants to expand capacity in Richmond, Virginia Beach, and rural communities

Administration and evaluation (10%): $32 million

• Oversight staff, data tracking, program evaluation
• This is within acceptable limits, but some advocates argue it's too high

Virginia's approach has been relatively evidence-based compared to some states. The focus on increasing Medicaid coverage for Suboxone treatment and expanding telehealth access directly addressed barriers patients face. But prevention spending has been controversial — some programs focus on abstinence messaging rather than harm reduction.

Ohio: The OneOhio Model

Ohio took a unique approach by creating the OneOhio Recovery Foundation, which manages $872 million in local allocations. This structure was supposed to prevent counties from spending funds on unproven programs, but it's been messy in practice.

Treatment expansion (41%): $462 million

• 89 new MAT programs opened across the state
• Ohio Medicaid coverage expanded for all FDA-approved addiction medications
• Mobile treatment units serving rural Appalachia and small cities like Canton and Youngstown
• $52 million to hospital emergency departments for "bridge" prescriptions (giving patients buprenorphine before they leave the ER)

Naloxone and harm reduction (19%): $214 million

• Naloxone distributed through libraries, schools, and community centers
• Syringe services programs expanded in Columbus, Cleveland, and Cincinnati
• Funding for harm reduction philosophy training for law enforcement (controversial but effective)

Recovery support services (16%): $180 million

• Peer recovery coaching programs
• Transportation vouchers for treatment appointments
• Employment readiness training

Prevention (14%): $158 million

• Youth prevention programs with mixed evidence
• Prescription drug monitoring improvements
• Safe disposal sites for unused medications

Administration (10%): $113 million

• OneOhio Foundation staffing and regional coordinators
• This is the highest admin percentage of the three states and has drawn criticism

Ohio's bridge prescription funding has been particularly successful. Studies show that patients who receive buprenorphine in the ER are 30% more likely to stay engaged in treatment after 30 days. But the state's prevention spending has been less effective — millions went to programs that focus on "just say no" messaging rather than evidence-based approaches.

Start your treatment journey with Grata Health — same-day appointments, most insurance accepted.

Pennsylvania: A Slower Rollout

Pennsylvania's settlement spending started slowly due to bureaucratic delays, but picked up in 2025. The state allocated funds through the Pennsylvania Opioid Misuse and Addiction Abatement Trust.

Treatment expansion (35%): $225 million

• 67 new outpatient MAT programs opened statewide
• Medicaid reimbursement increased for counseling alongside medication
• Grants to primary care practices to add buprenorphine prescribing capacity
• Telehealth expansion in rural counties and smaller cities like Reading, Scranton, and Lancaster

Naloxone access (24%): $154 million

• Standing order allowing pharmacies to dispense naloxone without individual prescriptions
• Free naloxone in all public libraries and community centers
• Training for families and people in recovery

Criminal justice diversion (15%): $96 million

• Pre-arrest diversion programs connecting people to treatment instead of jail
• Medication continuation programs in county jails
• Reentry support for people leaving incarceration

Prevention and education (14%): $90 million

• School-based programs with mixed effectiveness
• Stigma reduction campaigns
• Provider education on safer prescribing practices

Recovery housing (7%): $45 million

• Standards and certification for recovery residences
• Capacity expansion in Philadelphia and Pittsburgh

Administration (5%): $33 million

• Lowest admin percentage of the three states
• Managed through existing state departments

Pennsylvania's slower start meant fewer funds were spent by early 2026, but the state's focus on criminal justice diversion has been promising. Counties with pre-arrest diversion programs saw 40% fewer overdose deaths among people who would have been arrested for drug possession.

What's Working: Evidence-Based Investments

Across all three states, certain types of spending have shown clear impact:

Expanding MAT access. More providers, more telehealth options, and better insurance coverage for Suboxone directly reduce overdose deaths. This is the most evidence-backed use of settlement funds.

Free naloxone distribution. Making naloxone available without barriers saves lives. Period. States that increased naloxone access saw overdose reversals increase by 35–50%.

Bridge prescriptions in emergency departments. Giving patients buprenorphine before they leave the hospital dramatically increases treatment engagement.

Criminal justice diversion. Getting people into treatment instead of jail reduces recidivism and overdose risk.

Recovery housing standards. Creating certification requirements ensures safe, supportive environments rather than exploitative "sober living" scams.

What Isn't Working: Wasted Opportunities

Some settlement spending has been less effective or even counterproductive:

Abstinence-only prevention programs. Millions went to school programs that ignore harm reduction and medication-assisted treatment. Research shows these don't reduce drug use and can increase stigma.

Pilot programs that never scale. States love funding small "innovative" programs that generate press releases but never expand to serve more than a handful of people.

Administrative bloat. While some overhead is necessary, states spending 10%+ on administration are diverting money from direct services.

Barriers to MAT access remain. Despite settlement funding, prior authorization requirements, restrictive insurance policies, and provider shortages still make it hard to get treatment in rural areas.

Ignoring harm reduction. Some counties explicitly refused to fund syringe services or other harm reduction programs due to political opposition, even though these interventions reduce disease transmission and connect people to treatment.

Are the Funds Reaching Patients?

This is the most important question. Settlement money looks impressive on spreadsheets, but does it translate to someone in Toledo or Newport News being able to access Suboxone treatment when they need it?

The answer is: sometimes. In areas where settlement funds went toward expanding Medicaid coverage, increasing provider capacity, and launching telehealth programs, yes — patients have more options. Grata Health and similar providers have been able to serve more people because of improved reimbursement and policy changes funded by settlements.

But in rural counties, small towns, and areas where local officials prioritized prevention over treatment, access remains limited. A person struggling with opioid use disorder in rural Appalachia might see billboards about "saying no to drugs" funded by settlement money, but still have to drive two hours to find a Suboxone provider.

How to Advocate for Better Settlement Spending

If you want settlement funds in your community to support evidence-based treatment, here's what you can do:

Find out how your county is spending funds. Most states publish settlement spending dashboards online. Search "[your state] opioid settlement tracker" to see where the money is going.

Attend local opioid task force meetings. Most counties have advisory boards that make recommendations on settlement spending. These meetings are public. Show up and share your perspective.

Support harm reduction organizations. Nonprofits doing syringe exchange, naloxone distribution, and peer support need settlement funding. If your local government isn't prioritizing this, say so.

Contact your state legislators. Email or call your representatives and tell them to support MAT expansion, not abstinence-only prevention. Use your own story if you're comfortable — personal narratives move policy.

Share what worked for you. If telehealth treatment, counseling alongside medication, or a specific program helped you or someone you love, tell that story publicly. It counters stigma and shows officials what works.

Push back on stigmatizing language. When officials talk about "tough love" or funding programs that exclude medication-assisted treatment, call it out. Evidence matters more than ideology.

What to Watch in 2026 and Beyond

Settlement funds will continue flowing through 2038, but the next few years are critical for establishing spending patterns. Here's what to pay attention to:

MAT capacity in rural areas. Will settlement money reach places where providers are scarce, or will it concentrate in cities?

Medicaid reimbursement rates. States can use settlement funds to supplement Medicaid payments, making it financially viable for more doctors to prescribe buprenorphine. This is one of the highest-impact uses of the money.

Harm reduction expansion. Will states follow evidence and fund syringe services, or will political opposition continue blocking proven interventions?

Prevention effectiveness. As years pass, we'll see outcome data on school programs and public awareness campaigns. Evidence-based approaches should get more funding; ineffective ones should be cut.

Accountability and transparency. Will states publish clear data on how funds are spent and what results they produce? Or will spending disappear into vague categories with no measurable outcomes?

The Bottom Line: Money Alone Isn't Enough

Opioid settlements represent the largest public health investment in addiction treatment in U.S. history. But money doesn't automatically translate to lives saved. It depends on whether states prioritize evidence over politics, treatment over punishment, and access over stigma.

In Virginia, Ohio, and Pennsylvania, we've seen both progress and missed opportunities. More people can access medication-assisted treatment than five years ago. Naloxone is more widely available. But barriers remain, especially in rural communities and among populations facing the most stigma.

If you're reading this because you or someone you love needs treatment, don't wait for your state to spend settlement money perfectly. Start your treatment journey today — Grata Health offers same-day telehealth appointments in Virginia, Ohio, and Pennsylvania, with most insurance plans accepted including Medicaid, Aetna, and Blue Cross Blue Shield.

Recovery is possible right now, with the right support. Settlement funds should make that easier, but they're no substitute for taking the first step.